Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart and Vessels
Erschienen in: Heart and Vessels 1/2019

03.08.2018 | Correction

Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese

verfasst von: Daisuke Nose, Yuhei Shiga, Yoko Ueda, Yoshiaki Idemoto, Kohei Tashiro, Yasusnori Suematsu, Takashi Kuwano, Ken Kitajima, Keijiro Saku, Shin-ichiro Miura

Erschienen in: Heart and Vessels | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In the original publication of the article, Tables 1, 2 and 3 was published incorrectly. Unnecessary inequality symbols were added to all the numbers in the ‘p value’ of Tables 1, 2 and 3. The correct Tables 1, 2 and 3 should be as follows,
Table 1
Patient characteristics in all patients, non-CAD and CAD groups
 
All patients (n = 393)
Non-CAD group (n = 182)
CAD group (n = 211)
p value non-CAD vs. CAD
Age, years
66 (59–73)
63 (56–70)
69 (61–75)
< 0.0001
Sex male, % (n)
51 (202)
45 (82)
57 (120)
0.019
BMI, kg/m2
24 (22–26)
24 (22–26)
23 (21–26)
0.21
Family history, % (n)
26 (102)
24 (44)
27 (58)
0.46
Smoking, % (n)
38 (149)
33 (60)
42 (89)
0.061
HTN, % (n)
72 (283)
63 (115)
80 (168)
0.0003
DM, % (n)
23 (89)
16 (29)
28 (60)
0.003
DL, % (n)
67 (262)
62 (113)
71 (149)
0.074
CKD, % (n)
31 (124)
25 (46)
37 (78)
0.013
TG, mg/dl
117 (87–158)
109 (79–154)
124 (94–163)
0.017
LDL-C, mg/dl
115 ± 30
115 ± 30
114 ± 29
0.78
HDL-C, mg/dl
51 (44–62)
54 (45–66)
50 (43–59)
0.002
HbA1c, % (n)
5.7 (5.4–6.2)
5.7 (5.3–6.1)
5.9 (5.5–6.4)
0.0003
Fasting glucose, mg/dl
100 (93–113)
99 (93–107)
102 (93–121)
0.041
UA, mg/dl
5.4 (4.5–6.3)
5.4 (4.5–6.3)
5.4 (4.5–6.3)
0.93
eGFR, ml/min/1.73 m2
67 (57–77)
70 (60–80)
64 (55–75)
0.002
PCSK9, ng/ml
213 (169–268)
203 (156–257)
223 (172–278)
0.006
Log PCSK9
5.35 ± 0.36
5.29 ± 0.39
5.40 ± 0.33
0.004
Medication
       
 ARB, % (n)
38 (149)
31 (56)
44 (93)
0.007
 ACE-I, % (n)
3 (12)
2 (3)
4 (9)
0.12
 CCB, % (n)
36 (141)
27 (50)
43 (91)
0.001
 BB, % (n)
11 (43)
7 (12)
15 (31)
0.009
 Diuretic, % (n)
10 (41)
9 (17)
11 (24)
0.51
 Statin, % (n)
34 (134)
27 (50)
40 (84)
0.01
 SU, % (n)
9 (39)
7 (12)
13 (27)
0.037
 BG, % (n)
6 (24)
6 (11)
6 (13)
0.96
 DPP4-I, % (n)
11 (43)
8 (14)
14 (29)
0.052
Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal distribution, the variables are expressed as a median value and interquartile range
CAD coronary artery disease, BMI body mass index, HTN hypertension, DM diabetes mellitus, DL dyslipidemia, CKD chronic kidney disease, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c, UA uric acid, eGFR estimated glomerular filtration rate, PCSK9 pro-protein convertase subtilisin/kexin type 9, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, BB beta-blocker, DU diuretic, SU sulfonylurea, BG biguanide, DPP4-I dipeptidyl-peptidase 4 inhibitor
Table 2
Patient characteristics of all patients, the patients with non-CAD and CAD in the non-statin and statin groups
 
Non-statin group (n = 259)
Statin group (n = 134)
All patients (n = 259)
Non-CAD group (n = 132)
CAD group (n = 127)
p value non-CAD vs. CAD
All patients (n = 134)
Non-CAD group (n = 50)
CAD group (n = 84)
p value non-CAD vs. CAD
Age, years
65 (58–73)
63 (55–70)
69 (60–75)
< 0.0001
67 (60–74)
64 (58–71)
69 (62–75)
0.059
Male, % (n)
52 (134)
45 (59)
59 (75)
0.021
51 (68)
46 (23)
54 (45)
0.40
BMI, kg/m2
23 (21–26)
24 (22–26)
23 (21–26)
0.22
24 (22–26)
24 (22–27)
24 (22–26)
0.39
Family history, % (n)
24 (63)
25 (33)
24 (30)
0.80
29 (39)
22 (11)
33 (28)
0.16
Smoking, % (n)
39 (102)
33 (44)
46 (58)
0.042
35 (47)
32 (16)
37 (31)
0.57
HTN, % (n)
67 (173)
60 (79)
74 (94)
0.016
82 (110)**
72 (36)
88 (74)
0.019
DM, % (n)
18 (47)
14 (18)
23 (29)
0.055
31 (42)**
22 (11)
37 (31)
0.072
DL, % (n)
49 (128)
48 (63)
51 (65)
0.58
100 (134)**
100
100
 
CKD, % (n)
31 (79)
24 (32)
37 (47)
0.026
34 (45)
26 (13)
37 (31)
0.19
TG, mg/dl
117 (87–158)
108 (79–154)
125 (96–162)
0.042
117 (90–163)
112 (78–156)
124 (93–166)
0.16
LDL-C, mg/dl
119 ± 30
117 ± 27
120 ± 32
0.362
107 ± 27**
110 ± 35
104 ± 23
0.27
HDL-C, mg/dl
51 (44–63)
53 (45–68)
49 (42–58)
0.005
52 (45–62)
54 (47–62)
51 (44–61)
0.31
HbA1c, %
5.7 (5.3–6.2)
5.6 (5.3–6.0)
5.8 (5.5–6.3)
0.002
5.9 (5.5–6.5)**
5.8 (5.6–6.3)
5.9 (5.5–6.8)
0.19
Fasting glucose, mg/dl
100 (93–112)
100 (94–108)
102 (93–118)
0.19
99 (93–116)
98 (92–105)
102 (93–127)
0.089
UA, mg/dl
5.4 (4.5–6.2)
5.3 (4.5–6.2)
5.4 (4.5–6.3)
0.61
5.6 (4.5–6.5)
5.7 (4.5–7.8)
5.5 (4.5–6.3)
0.22
eGFR, ml/min/1.73 m2
68 (57–78)
70 (61–82)
65 (55–76)
0.019
64 (57–75)
68 (59–77)
64 (55–73)
0.064
PCSK9, ng/ml
196 (159–247)
182 (150–235)
213 (169–261)
0.003
252 (201–303)**
252 (210–294)
253 (197–304)
0.67
Log PCSK9
5.28 ± 0.34
5.21 ± 0.36
5.35 ± 0.31
0.0008
5.49 ± 0.37**
5.51 ± 0.40
5.47 ± 0.34
0.51
CAD, % (n)
49 (127)
     
63 (84)*
     
VD 0
 
100 (132)
0
   
100
0
 
VD 1
 
0
45 (57)
   
0
32 (27)
 
VD 2 + 3
 
0
55 (70)
   
0
68 (57)
 
Gensini score
 
2.5 (0–6)
15 (10–23)
< 0.0001
 
2.5 (0–6)
18 (13–27)
< 0.0001
Medication
               
 ARB, % (n)
29 (76)
26 (33)
34 (43)
0.12
54 (73)**
46 (23)
60 (50)
0.13
 ACE-I, % (n)
2 (3)
2 (2)
2 (3)
0.62
5 (7)
2 (1)
7 (6)
0.17
 CCB, % (n)
31 (81)
23 (30)
40 (51)
0.002
45 (60)**
40 (20)
48 (40)
0.39
 BB, % (n)
8 (22)
7 (9)
10 (13)
0.32
16 (21)*
6 (3)
21 (18)
0.012
 Diuretic, % (n)
10 (27)
11 (14)
10 (13)
0.92
10 (14)
6 (3)
13 (11)
0.18
 SU, % (n)
7 (19)
6 (8)
9 (11)
0.42
15 (20)
8 (4)
19 (16)
0.071
 BG, % (n)
4 (11)
5 (6)
4 (5)
0.81
10 (13)
10 (5)
10 (8)
0.93
 DPP4-I, % (n)
9 (23)
8 (10)
10 (13)
0.45
15 (20)
8 (4)
19 (16)
0.071
Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal distribution, the variables are expressed as a median value and interquartile range
CAD coronary artery disease, BMI body mass index, HTN hypertension, DM diabetes mellitus, DL dyslipidemia, CKD chronic kidney disease, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c, UA uric acid, eGFR estimated glomerular filtration rate, PCSK9 pro-protein convertase subtilisin/kexin type 9, VD vessel disease (the number of significantly stenosed coronary vessels), ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, BB, beta-blocker, DU diuretic, SU sulfonylurea, BG biguanide, DPP4-I dipeptidyl-peptidase 4 inhibitor
*p < 0.05 vs. all patients in the non-statin group
**p < 0.01 vs. all patients in the non-statin group
Table 3
The univariable and multivariable logistic regression analysis regarding the association with CAD in all patients, the statin and non-statin groups
All patients
Variables
Univariable
Multivariable
OR
95% CI
p
OR
95% CI
p
Age
1.05
1.03–1.07
< 0.0001
1.05
1.02–1.08
< 0.0001
Male
1.61
0.42–0.92
0.020
2.10
1.21–3.65
0.007
BMI
0.96
0.90–1.01
0.12
0.92
0.86–0.99
0.021
Family history
1.19
0.75–1.87
0.45
1.34
0.80–2.24
0.26
Smoking
1.48
0.98–2.24
0.06
1.12
0.65–1.94
0.67
HTN
2.28
1.45–3.57
0.0003
1.62
0.95–2.75
0.075
DM
2.10
1.28–3.45
0.003
2.20
1.24–3.91
0.006
CKD
1.73
1.12–2.68
0.013
1.11
0.67–1.85
0.69
Log PCSK9
2.27
1.27–4.01
0.004
2.65
1.36–5.14
0.003
Statin
1.75
1.14–2.67
0.010
1.45
0.87–2.40
0.15
HDL-C
0.98
0.96–0.99
0.0005
0.98
0.96–0.99
0.008
LDL-C
1.00
0.99–1.01
0.78
1.01
1.00–1.01
0.18
Statin group
Variables
Univariable
Multivariable
OR
95% CI
p
OR
95% CI
p
Age
1.04
1.00–1.07
0.034
1.03
0.98–1.07
0.26
Male
1.35
0.67–2.73
0.40
1.44
0.52–3.98
0.48
BMI
0.37
0.057–2.43
0.30
0.88
0.77–1.00
0.047
Family history
1.77
0.79–3.98
0.16
2.24
0.89–5.62
0.078
Smoking
1.24
0.59–2.61
0.56
1.30
0.48–3.56
0.61
HTN
2.88
1.17–7.11
0.021
2.01
0.70–5.77
0.19
DM
2.07
0.93–4.63
0.068
3.31
1.24–8.84
0.013
CKD
1.66
0.78–3.69
0.20
1.46
0.57–3.75
0.43
Log PCSK9
0.72
0.27–1.91
0.51
0.66
0.22–1.98
0.45
HDL-C
1.00
0.97–1.02
0.69
0.99
0.96–1.02
0.60
LDL-C
0.99
0.98–1.02
0.27
0.99
0.98–1.01
0.37
Non-statin group
Variables
Univariable
Multivariable
OR
95% CI
p
OR
95% CI
p
Age
1.05
1.03–1.08
< 0.0001
1.07
1.04–1.11
< 0.0001
Male
1.78
1.09–2.92
0.021
3.03
1.46–6.29
0.002
BMI
0.95
0.89–1.02
0.15
0.91
0.83–1.00
0.049
Family history
0.93
0.53–1.64
0.8
1.04
0.53–2.02
0.91
Smoking
1.68
1.02–2.78
0.042
1.16
0.57–2.37
0.68
HTN
1.91
1.13–3.24
0.015
1.51
0.80–2.85
0.21
DM
1.87
0.98–3.58
0.054
1.65
0.76–3.57
0.20
CKD
1.84
1.07–3.14
0.027
0.91
0.47–1.75
0.77
Log PCSK9
3.65
1.67–7.99
0.0007
6.23
2.44–15.9
< 0.0001
HDL-C
0.97
0.95–0.99
0.0006
0.97
0.95–0.99
0.003
LDL-C
1.00
1.00–1.01
0.38
1.01
1.00–1.02
0.022
CAD coronary artery disease, OR odds ratio, CI confidence Interval, BMI body mass index, HTN hypertension, DM diabetes mellitus, CKD chronic kidney disease, PCSK9 pro-protein convertase subtilisin/kexin type 9, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
…
Metadaten
Titel
Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese
verfasst von
Daisuke Nose
Yuhei Shiga
Yoko Ueda
Yoshiaki Idemoto
Kohei Tashiro
Yasusnori Suematsu
Takashi Kuwano
Ken Kitajima
Keijiro Saku
Shin-ichiro Miura
Publikationsdatum
03.08.2018
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2019
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-018-1237-y

Weitere Artikel der Ausgabe 1/2019

Heart and Vessels 1/2019 Zur Ausgabe

Original Article

Functional analysis of KCNH2 gene mutations of type 2 long QT syndrome in larval zebrafish using microscopy and electrocardiography

Original Article

Sustained delivery of vascular endothelial growth factor using a dextran/poly(lactic-co-glycolic acid)-combined microsphere system for therapeutic neovascularization

Original Article

Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese

Original Article

Stroke volume ratio derived from magnetic resonance imaging as an indicator of interventricular dyssynchrony predicts future cardiac event in patients with biventricular Fontan circulation

Original Article

Impact of the angiographic burden on the incidence of out-of-hospital ventricular fibrillation in patients with acute myocardial infarction

Original Article

Factors causing prolonged mechanical ventilation and peri-operative morbidity after robot-assisted coronary artery bypass graft surgery

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise